en بیماری های دهان Oral Medicine پژوهشي Research <p> <strong>Objectives</strong> To describe the natural course of distant metastases (DMs) following radiotherapy (RT) or chemoradiotherapy (CRT) in HPV(+) oropharyngeal carcinoma (OPC). </p><p> <strong>Methods</strong> OPC treated with RT/CRT from 1/1/2000 to 5/31/2010 were reviewed. The natural course of DM were compared between HPV(+) and HPV(−) cohorts. </p><p> <strong>Results</strong> Median follow-up was 3.9years. The DM rate were similar (11% vs. 15% at 3-years, p=0.25) between the HPV(+) (n=457) vs. the HPV(−) (n=167) cases. While almost all (24/25) HPV(−) DM occurred within 2-years following RT (1 was at 2.1years), 7/54 (13%) of HPV(+) DM were detected beyond 3years (up to 5.3years). Disseminating to >2 organs occurred in 18 (33%) HPV(+) vs. none in HPV(−). Post-DM survival rates were 11% vs. 4% at 2-years (p=0.02) for the HPV(+) vs. HPV(−) cases respectively. 5/6 HPV(+) with lung oligo-metastasis were still alive with stable disease beyond 2-years after salvage procedures for DM (chemotherapy: 3 surgical resection: 2 radiotherapy: 1). <strong></strong></p><p> <strong>Conclusions</strong> Although DM rates are similar, the natural course of HPV(+) DM differs from that of HPV(−) patients: it may occur after a longer interval, often with a “disseminating” phenotype, and a small number may have prolonged survival after salvage for DM. </p><hr><p></p><p> <strong>Source: </strong>Journal of Oral Oncology </p><p><a href="http://www.oraloncology.com/article/S1368-8375(12)00243-6/abstract" target="_blank"><font color="#0033ff">Full Text</font></a></p> Human papillomavirus, Oropharyngeal carcinoma, Distant metastasis, Radiotherapy, Chemoradiotherapy 0 0 http://idai.ir/browse.php?a_code=A-10-32-860&slc_lang=en&sid=1 Shao Hui Huang 10031947532846003756 10031947532846003756 Yes Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada Bayardo Perez-Ordonez 10031947532846003757 10031947532846003757 No Department of Pathology, University Health Network, Toronto, Canada Ilan Weinreb 10031947532846003758 10031947532846003758 No Department of Pathology, University Health Network, Toronto, Canada Andrew Hope 10031947532846003759 10031947532846003759 No Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada Christine Massey 10031947532846003760 10031947532846003760 No Department of Biostatistics, Princess Margaret Hospital, Toronto, Canada John N. Waldron 10031947532846003761 10031947532846003761 No Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada John Kim 10031947532846003762 10031947532846003762 No Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada Andrew J. Bayley 10031947532846003763 10031947532846003763 No Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada Bernard Cummings 10031947532846003764 10031947532846003764 No Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada Brian O’Sullivan 10031947532846003765 10031947532846003765 No Department of Radiation Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada